Acrivon Therapeutics Inc....

NASDAQ: ACRV · Real-Time Price · USD
1.36
-0.03 (-2.16%)
At close: Aug 15, 2025, 3:39 PM

Acrivon Therapeutics Common Stock Income Statement

Financials in USD. Fiscal year is undefined.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021
Revenue
n/a n/a 848K n/a n/a n/a 1.88M n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
n/a 311K 303K 300K 200K 224K 149K 331K 295K 316K 313K 300K 259K 223K n/a 261K
Gross Profit
n/a -311K 424K -300K -200K -224K -149K -331K -295K -316K -313K -300K -259K -223K n/a -261K
Operating Income
-22.65M -21.66M -24.95M -25.14M -21.44M -17.67M -21.05M -16.14M -15.52M -14.39M -9.95M -9.57M -5.92M -7.21M -4.27M -2.67M
Interest Income
1.73M 2M 2.36M 2.7M 2.69M 1.45M n/a 1.77M 1.77M 1.81M n/a n/a n/a n/a n/a n/a
Pretax Income
-21.01M -19.68M -22.83M -22.44M -18.8M -16.49M -19.25M -14.47M -13.91M -12.76M -8.93M -9.2M -5.82M -7.22M -4.34M -2.44M
Net Income
-21.01M -19.68M -22.83M -22.44M -18.8M -16.49M -19.25M -14.47M -13.91M -11.12M -7.91M -8.82M -5.71M -7.23M -4.42M -2.21M
Selling & General & Admin
6.47M 6.25M 6.32M 6.28M 6.41M 6.2M 5.58M 6M 5M 4.63M 4.08M 1.63M 1.85M 1.14M 1.22M 455K
Research & Development
16.18M 15.41M 18.33M 18.86M 15.03M 11.25M 15.33M 9.88M 10.52M 9.76M 5.86M 7.94M 4.08M 6.07M 3.05M 2.22M
Other Expenses
n/a -311K n/a n/a -200K n/a n/a n/a 1.61M 1.64M 1.02M 377K 105K -8K n/a 231K
Operating Expenses
22.65M 21.35M 24.65M 25.14M 21.24M 17.44M 20.9M 15.88M 15.52M 14.39M 9.95M 9.57M 5.92M 7.21M 4.27M 2.67M
Interest Expense
n/a n/a n/a n/a n/a n/a 1.64M n/a n/a n/a n/a n/a n/a 8K 73K n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
n/a 21.66M 24.95M 25.14M 21.44M 17.67M 21.05M 16.14M 15.52M 14.39M 9.95M 9.57M 5.92M 7.21M 4.27M 2.67M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a 6.92K -1.64M -1.02M -377K -105K 8K 73K -231K
Shares Outstanding (Basic)
38.46M 38.35M 38.24M 38.11M 36.13M 22.59M 22.34M 22.08M 21.97M 21.92M 20.88M 18.81M 12.91M 12.91M 12.91M 12.91M
Shares Outstanding (Diluted)
38.46M 38.35M 38.24M 38.11M 36.13M 22.59M 22.34M 22.08M 21.97M 21.92M 20.88M 18.81M 12.91M 12.91M 12.91M 12.91M
EPS (Basic)
-0.55 -0.51 -0.6 -0.59 -0.52 -0.73 -0.86 -0.66 -0.63 -0.51 -0.38 -0.47 -0.44 -0.56 -0.34 -0.17
EPS (Diluted)
-0.55 -0.51 -0.6 -0.59 -0.52 -0.73 -0.86 -0.66 -0.63 -0.51 -0.38 -0.47 -0.44 -0.56 -0.34 -0.17
EBITDA
-22.65M -21.66M -24.65M -24.89M -12.57M -17.44M -20.9M -14.13M -15.52M -14.39M -9.82M -9.46M -5.85M -7M -4.26M -2.66M
EBIT
n/a -19.68M -24.95M -25.14M -12.79M -17.67M -21.05M -14.47M -15.52M -14.39M -9.95M -9.57M -5.92M -7.21M -4.27M -2.67M
Depreciation & Amortization
n/a 311K 303K 300K 228K 224K 149K 331K 295K 316K 313K 300K 259K 223K 13K 261K